Videos

The panel of experts in prostate cancer offers a comprehensive overview of prostate cancer diagnosis, emphasizing the role of prostate-specific antigen (PSA) testing in screening for the disease.

"The cases that I've done have been here, at least, have been some of the most, I guess, impactful and really make me proud and happy to be a urologist and to do something [for which] the patients are incredibly grateful," says John Michael DiBianco, MD.

"We did see a rise in 2020, and that's been kind of maintained in 2021 and 2022, but overall, it looked like a pretty low rate," says Brian R. Lane, MD, PhD, FACS.

"My goal in the trip was not to see how many patients I could operate on, how many doctors I could train, [it was] to help 1 person train," says Joel Gelman, MD.

“We get exposure and get an opportunity to work with experts in the field before we even start fellowship, so that we can develop a baseline of expertise in areas of Peyronie's disease, erectile dysfunction, infertility, and managing sexual medicine and fertility in men across the board,” says Jacob Rust, MD.

"A surprise finding was the increase in opioid fulfillment beyond the 7-day postoperative period, which was really unexpected," says Laura Gressler, MS, PhD.

"I think it really is going to change my practice," says Akhil Das, MD, FACS.

Stephen Freedland, MD, reviews findings from the EMBARK study, which investigated enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer.

3. Terence Friedlander, MD, provides clinical insights on factors that inform the role for androgen deprivation therapy in the treatment of patients with localized or locally advanced prostate cancer.

“Fortunately, the chemotherapy regimens that Dr. Einhorn put together in combination with the surgical approaches with Dr. Donohue really revolutionized the cure rates and the care for men with testicular cancer,” says Clint Cary, MD, MPH, MBA.

Experts discuss available therapies beyond BCG.

Experts discuss the rate of recurrence following first-line BCG therapy.

"It's the creating of things for me that drives me. Even my wife tells me, 'You are most happy when you're creating new things,' " says Steven A. Kaplan, MD.

“It's been exciting to be on the forefront of new technology and new implants to help men regain their sexual function and empower them,” says Dr. Helen L. Bernie, DO, MPH.

"When it came down to linking the clinical information with both biopsy reports as well as the prostatectomy pathology reports, we didn't have much of a challenge with that," says Randy A. Vince Jr, MD, MS.

"Unless there's an anatomic reason why you can't use a bladder scanner reliably, then, really you should be using a bladder scanner," says Jennifer Ann Meddings, MD, MSc.

"Access to clean water and having reliable sewage systems is a huge public health issue," says Elisabeth M. Sebesta, MD.

“We will do exactly what we have done in terms of prototype of our processes, our tools, our design, and how we follow these patients up, and expand this from 10,000 men in less than 2 years to 1 million men in next 10 years,” says Ashutosh K. Tewari, MD.

"You definitely need to be very adaptable. You have to have a great team," says John Michael DiBianco, MD.

"I'm very transparent with my patients by telling them these exist. I don't provide them because we don't have enough level of evidence or body of research supporting them," says Ramy Abou Ghayda, MD, MPH, MBA.

"My goal as a 'plumber'/urologist is to see if we can find better options and also understand the mechanism behind the disease," says Zhina Sadeghi, MD.

“This is a great opportunity for public outreach and re-education on the common misconceptions surrounding vasectomy,” says Catherine S. Nam, MD.

Kyrollis Attalla, MD, remarks on emerging imaging technologies for patients with prostate cancer and the growing pool of candidates for focal therapy.

An expert on prostate cancer discusses how fusion-guided biopsy can help determine patient eligibility for focal therapy.

"For [men] to come to the practice and talk about [a sensitive issue] is a big step," says Adity Dutta, MSN, AGACNP-BC.

"What we found is that across the board, all 16 scores did relatively well with the association between an elevated polygenic risk score and prostate cancer incidence," says Randy A. Vince Jr, MD, MS.

Experts on prostate cancer discuss the heterogeneity of the disease and the rationale for using medications with different mechanisms of action, including androgen deprivation therapy.

Lawrence Karsh, MD, FACS, introduces a discussion on prostate cancer and androgen deprivation therapy with an overview of how the treatment landscape has changed in recent years.

“One thing is we’re trying to create an atmosphere in the center whereby men feel at ease, they're comfortable talking to their provider who is specialized in this field,” says Ramy Abou Ghayda, MD, MPH, MBA.

Trinity Bivalacqua, MD, PhD and Mark Tyson, MD, MPH discuss the current shortage of BCG therapy and how that has impacted clinical practice management.